Dapagliflozin in Active Lupus Nephritis
Purpose
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.
Condition
- Lupus Nephritis (LN)
Eligibility
- Eligible Ages
- Between 18 Years and 70 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- • Age 18-70 years, fulfilling 2012 SLICC or 2019 ACR/EULAR criteria for SLE, with biopsy-proven class III, IV and/or V LN - Active (new or relapsing) LN within the prior six months, with at least one of the following: - Kidney biopsy with activity index >2 and/or - Active urinary sediment (>5 RBCs, >5 WBCs, or cellular casts) - Receiving standard-of-care immunosuppression regimen for active LN, including mycophenolate, cyclophosphamide, belimumab, azathioprine, a calcineurin inhibitor, and/or B cell depleting therapies - Recent or ongoing glucocorticoids use for active LN within the past 6 months - Receiving standard-of-care antimalarial therapy and RAAS blockade, unless contraindicated - Estimated ≥0.5 g/g 24 hr proteinuria or ≥0.3 mg/g 24 hr microalbuminuria at enrollment (on first morning urine) - Ability to given informed consent
Exclusion Criteria
- GFR < 25 ml/min/1.73m2 - Acute kidney injury at study enrollment (>50 percent rise in creatinine within 90 days) - Type I diabetes, underweight (BMI <18.5), active malignancy, active infection, or recurrent genitourinary infections - For females: pregnancy, or desiring of pregnancy and not using contraception, or unable to use contraception - Current use of >1mg/kg/day prednisone equivalent - Current or prior use of SGLT2 inhibitors or GLP-1 receptor agonists
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Pilot and feasibility, concealed allocation, blinded randomized controlled trial of dapagliflozin 10 mg/day or matched placebo in a 2:1 allocation ratio (22 subjects active arm: 11 subjects placebo arm), in addition to standard-of-care treatment, for 12 weeks.
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Dapagliflozin 10 mg daily |
Subjects will receive masked dapagliflozin 10 mg daily for 12 weeks |
|
|
Placebo Comparator Matching placebo pill daily |
Subjects will receive a matching placebo pill to take daily for 12 weeks |
|
Recruiting Locations
Boston, Massachusetts 02114
More Details
- Status
- Recruiting
- Sponsor
- Brigham and Women's Hospital
Detailed Description
This is a pilot and feasibility randomized, double-blind, placebo-controlled trial involving patients with active lupus nephritis. It will be a concealed allocation, blinded randomized controlled trial of dapagliflozin 10 mg/day or matched placebo in a 2:1 allocation ratio (22 subjects active arm: 11 subjects placebo arm), in addition to standard-of-care treatment, for 12 weeks. After informed consent, 33 eligible subjects will be randomized 2:1 to oral dapagliflozin 10 mg/day or identical oral placebo/day for 12 weeks. Study visits will occur at screening (Visit -1), baseline (Visit 0) and weeks 4 (Visit 1), 8 (Visit 2) and 12 (Visit 3). Observational data including laboratory test results obtained in routine clinical care will be collected through 12 months of follow-up. The primary outcomes are: 1. the overall proportion of identified as potentially eligible/pre-screened patients who enroll in the trial; 2. feasibility and completeness of data collection procedures; 3. changes in urine protein-to-creatinine ratio (UPCR) and precision of these estimates from baseline to week 12 in each group; and 4. rates and proportions of serious adverse events and of adverse events of interest, including genitourinary infections and volume depletion.